Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Ruxolitinib is named as an intervention in 49 current clinical trials in our USA, China, UK, India and Ireland registers. 26 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Incyte Corporation (16). The most-studied condition is Myelofibrosis.

Ruxolitinib also has an approved-drug profile on this site (FDA label data): Jakafi (Ruxolitinib) →

Trials by status

Recruiting2653%
Not yet open12%
Active, closed2245%

Trials by phase

Phase 31327%
Phase 11122%
Phase 21020%
Phase 1/2510%
Observational48%
Phase 436%
Not applicable24%
Phase EARLY_PHASE112%

Clinical trials of Ruxolitinib

49 trials

Study	Phase	Status	Lead sponsor	Registers
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma NCT06209606 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase EARLY_PHASE1	Recruiting	Oncotherapeutics	USA
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease NCT06824103 · ClinicalTrials.gov ↗ · Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease	Phase 4	Recruiting	Novartis Pharmaceuticals	China
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib NCT06479135 · ClinicalTrials.gov ↗ · Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis	Phase 3	Recruiting	Kartos Therapeutics, Inc.	UK, USA
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo NCT06548360 · ClinicalTrials.gov ↗ · NonSegmental Vitiligo	Phase 3	Recruiting	Incyte Corporation	USA
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) NCT06615050 · ClinicalTrials.gov ↗ · Graft-versus-host Disease (GVHD)	Phase 3	Recruiting	Incyte Corporation	USA
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo NCT06804811 · ClinicalTrials.gov ↗ · NonSegmental Vitiligo	Phase 3	Recruiting	Incyte Corporation	UK
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) NCT07357727 · ClinicalTrials.gov ↗ · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)	Phase 3	Recruiting	Novartis Pharmaceuticals	USA, India, China
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis NCT05037760 · Myelofibrosis	Phase 2	Recruiting	Takeda	UK
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen NCT05088226 · ClinicalTrials.gov ↗ · Peripheral Blood Stem Cell Transplantation	Phase 2	Recruiting	Chinese PLA General Hospital	China
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV NCT05870475 · ClinicalTrials.gov ↗ · Polycythemia Vera	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia NCT05980806 · Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia	Phase 2	Recruiting	Karyopharm Therapeutics Inc	UK, USA
Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) NCT07340723 · ClinicalTrials.gov ↗ · GVHD,Acute, Stem Cell Transplant Complications	Phase 2	Recruiting	Daihong Liu	China
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis NCT04176198 · ClinicalTrials.gov ↗ · Myelofibrosis	Phase 1/2	Recruiting	Sumitomo Pharma America, Inc.	UK, USA
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib NCT05280509 · ClinicalTrials.gov ↗ · Myelofibrosis, Primary Myelofibrosis, Post-PV MF	Phase 1/2	Recruiting	Telios Pharma, Inc.	USA
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05745714 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	Phase 1/2	Recruiting	Princess Maxima Center for Pediatric Oncology	Ireland
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients NCT03110822 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1	Recruiting	Oncotherapeutics	USA
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms NCT06150157 · Neoplasms	Phase 1	Recruiting	Janssen Research & Development, LLC	UK, USA, China
A Trial of Selinexor, Ruxolitinib and Methylprednisolone NCT06225310 · ClinicalTrials.gov ↗ · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory	Phase 1	Recruiting	Oncotherapeutics	USA
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa NCT07049575 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa	Phase 1	Recruiting	Incyte Corporation	USA
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants NCT07588139 · ClinicalTrials.gov ↗ · Healthy Participants	Phase 1	Recruiting	Incyte Corporation	USA
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population NCT06259669 · ClinicalTrials.gov ↗ · Pregnancy Related, Atopic Dermatitis	Observational	Recruiting	Incyte Corporation	USA
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study NCT06573593 · ClinicalTrials.gov ↗ · Alopecia Areata, Janus Kinase Inhibitors	Observational	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis NCT06627335 · ClinicalTrials.gov ↗ · Pregnancy Related, Atopic Dermatitis	Observational	Recruiting	Incyte Corporation	USA
A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo NCT07153666 · ClinicalTrials.gov ↗ · Vitiligo	Observational	Recruiting	Peking University Third Hospital	China
MRD-positive AML Clinical Study NCT07131059 · ClinicalTrials.gov ↗ · AML, Adult	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD NCT07184853 · ClinicalTrials.gov ↗ · Graft vs Host Disease	Not applicable	Recruiting	First Affiliated Hospital of Zhejiang University	China
Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo NCT07595939 · ClinicalTrials.gov ↗ · Vitiligo	Phase 3	Not yet open	The Children's Hospital of Zhejiang University School of Medicine	China
CINC424A2X01B Rollover Protocol NCT02386800 · Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease	Phase 4	Active, closed	Novartis Pharmaceuticals	India, China
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease NCT06462469 · ClinicalTrials.gov ↗ · Steroid-refractory Acute Graft Versus Host Disease	Phase 4	Active, closed	Novartis Pharmaceuticals	China
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis NCT04468984 · ClinicalTrials.gov ↗ · Myelofibrosis (MF)	Phase 3	Active, closed	AbbVie	UK, USA, China
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis NCT04562389 · Myelofibrosis	Phase 3	Active, closed	Karyopharm Therapeutics Inc	UK, USA, China
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) NCT04603495 · ClinicalTrials.gov ↗ · Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis	Phase 3	Active, closed	Novartis Pharmaceuticals	UK, USA, China
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) NCT06079879 · ClinicalTrials.gov ↗ · Essential Thrombocythemia	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis NCT06832618 · ClinicalTrials.gov ↗ · Atopic Dermatitis	Phase 3	Active, closed	Incyte Corporation	UK, USA
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) NCT06958211 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa	Phase 3	Active, closed	Incyte Corporation	USA
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) NCT06959225 · Hidradenitis Suppurativa	Phase 3	Active, closed	Incyte Corporation	USA
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib NCT02955940 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer	Phase 2	Active, closed	Incyte Corporation	USA
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera NCT03669965 · ClinicalTrials.gov ↗ · Polycythemia Vera	Phase 2	Active, closed	Kartos Therapeutics, Inc.	USA
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) NCT04509700 · ClinicalTrials.gov ↗ · B-Cell Malignancies	Phase 2	Active, closed	Incyte Corporation	UK, USA
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease NCT06388564 · ClinicalTrials.gov ↗ · Chronic Graft-versus-host-disease	Phase 2	Active, closed	Incyte Corporation	UK, USA
A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis NCT06457425 · ClinicalTrials.gov ↗ · MF,PMF,PPV-MF,PET-MF	Phase 2	Active, closed	Chengdu Zenitar Biomedical Technology Co., Ltd	China
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders NCT04455841 · ClinicalTrials.gov ↗ · Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis	Phase 1/2	Active, closed	Incyte Corporation	UK, USA
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) NCT04817007 · ClinicalTrials.gov ↗ · Myelofibrosis	Phase 1/2	Active, closed	Bristol-Myers Squibb	USA
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm NCT04041050 · ClinicalTrials.gov ↗ · Myeloproliferative Neoplasm	Phase 1	Active, closed	AbbVie	UK, USA, China
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms NCT04279847 · ClinicalTrials.gov ↗ · Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome	Phase 1	Active, closed	Incyte Corporation	UK, USA, China
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers NCT04328844 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC	Phase 1	Active, closed	iOnctura	UK
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis NCT04454658 · Myelofibrosis (MF)	Phase 1	Active, closed	AbbVie	USA
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis NCT05371964 · Myelofibrosis	Phase 1	Active, closed	Geron Corporation	USA
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms NCT05936359 · ClinicalTrials.gov ↗ · Myeloproliferative Neoplasms	Phase 1	Active, closed	Incyte Corporation	UK

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Ruxolitinib across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

7 single-substance products containing Ruxolitinib on the HPRA medicines list.

JakaviNovartis Europharm Limited · EU/1/12/773/001
JakaviNovartis Europharm Limited · EU/1/12/773/002
Jakavi 10 mg tabletsNovartis Europharm Limited · EU/1/12/773/013-016
Jakavi 20 mg tabletsNovartis Europharm Limited · EU/1/12/773/003
Jakavi 5 mg tabletsNovartis Europharm Limited · EU/1/12/773/004-006

All 7 Irish products →

Supply shortages

No entry for Ruxolitinib in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Ruxolitinib

57 conditions

Myelofibrosis11Primary Myelofibrosis4Atopic Dermatitis3 Hidradenitis Suppurativa3Polycythemia Vera3Post-PV MF2Post-ET Myelofibrosis2NonSegmental Vitiligo2Myelofibrosis (MF)2Post-polycythemia Vera Myelofibrosis2Post-essential Thrombocythemia Myelofibrosis2Myeloproliferative Neoplasm2

All 57 conditions

Condition (as registered)	Trials
Myelofibrosis	11
Primary Myelofibrosis	4
Atopic Dermatitis	3
Hidradenitis Suppurativa	3
Polycythemia Vera	3
Post-PV MF	2
Post-ET Myelofibrosis	2
NonSegmental Vitiligo	2
Myelofibrosis (MF)	2
Post-polycythemia Vera Myelofibrosis	2
Post-essential Thrombocythemia Myelofibrosis	2
Myeloproliferative Neoplasm	2
Pregnancy Related	2
Multiple Myeloma	2
Vitiligo	2
Acute Lymphoblastic Leukemia, in Relapse	1
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent	1
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	1
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory	1
Moderate Thrombocytopenia	1
Mild Thrombocytopenia	1
Neoplasms	1
Chronic Graft-versus-host-disease	1
Essential Thrombocythemia	1
B-Cell Malignancies	1
Anemia	1
Solid Tumor, Adult	1
Non-Hodgkin Lymphoma, Adult	1
NSCLC	1
Myeloproliferative Neoplasms	1
Myelodysplastic Syndrome	1
Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome	1
Pancreatic Cancer	1
Colorectal Cancer (CRC)	1
Breast Cancer	1
Lung Cancer	1
Healthy Participants	1
Multiple Myeloma in Relapse	1
Multiple Myeloma, Refractory	1
Graft-versus-host Disease (GVHD)	1
Primary Myelofibrosis (PMF)	1
Post-polycythemia Vera Myelofibrosis (PPV-MF)	1
Post-essential Thrombocythemia Myelofibrosis (PET-MF)	1
Graft Versus Host Disease	1
Acute Myeloid Leukemia	1
Graft vs. Host Disease	1
Chronic Graft vs. Host Disease	1
Corticosteroid-refractory Chronic Graft vs. Host Disease	1
Steroid-refractory Acute Graft Versus Host Disease	1
GVHD,Acute	1
Stem Cell Transplant Complications	1
AML, Adult	1
Alopecia Areata	1
Janus Kinase Inhibitors	1
Graft vs Host Disease	1
Peripheral Blood Stem Cell Transplantation	1
MF,PMF,PPV-MF,PET-MF	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	32	15
Clinical trials in China	20	10
Clinical trials in UK	18	6
Clinical trials in India	2	1
Clinical trials in Ireland	1	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Ruxolitinib trials

How many clinical trials are testing Ruxolitinib?

49 current trials in our USA, China, UK, India and Ireland registers name Ruxolitinib (also registered as INC424) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Ruxolitinib trials recruiting patients?

Yes. 26 of the 49 trials are recruiting: 15 with sites in USA, 10 with sites in China, 6 with sites in UK, 1 with sites in India and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Ruxolitinib clinical trials?

Incyte Corporation (16), Novartis Pharmaceuticals (5), AbbVie (3) and Oncotherapeutics (3), among 23 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Ruxolitinib licensed in Ireland?

Yes. The HPRA medicines list includes 7 single-substance products containing Ruxolitinib, for example Jakavi (Novartis Europharm Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Ruxolitinib shortage?

Not in the lists we track: Ruxolitinib has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ruxolitinib works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ruxolitinib works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ruxolitinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Ruxolitinib clinical trials